Bvf Partners L P/il - Net Worth and Insider Trading

Bvf Partners L P/il Net Worth

The estimated net worth of Bvf Partners L P/il is at least $1.4 Billion dollars as of 2024-11-05. Bvf Partners L P/il is the 10% Owner of Array BioPharma Inc and owns about 12,965,657 shares of Array BioPharma Inc (ARRY) stock worth over $505 Million. Bvf Partners L P/il is the 10% Owner of Neurocrine Biosciences Inc and owns about 3,527,700 shares of Neurocrine Biosciences Inc (NBIX) stock worth over $425 Million. Bvf Partners L P/il is also the 10% Owner of Arqule Inc and owns about 16,832,292 shares of Arqule Inc (ARQL) stock worth over $337 Million. Besides these, Bvf Partners L P/il also holds ChemoCentryx Inc (CCXI) , Ligand Pharmaceuticals Inc (LGND) , BioCryst Pharmaceuticals Inc (BCRX) , Rigel Pharmaceuticals Inc (RIGL) , Arena Pharmaceuticals Inc (ARNA) , Dynavax Technologies Corp (DVAX) , Curis Inc (CRIS) , Catalyst Biosciences Inc (CBIO) , Capstone Holding Corp (CAPS) , Aeolus Pharmaceuticals Inc (AOLS) , Neurobiological Technologies Inc (NTII) . Details can be seen in Bvf Partners L P/il's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Bvf Partners L P/il has not made any transactions after 2015-06-10 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Bvf Partners L P/il

Bvf Partners L P/il Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Bvf Partners L P/il owns 52 companies in total, including Five Prime Therapeutics Inc (FPRX) , Eledon Pharmaceuticals Inc (ELDN) , and XOMA Royalty Corp (XOMA) among others .

Click here to see the complete history of Bvf Partners L P/il’s form 4 insider trades.

Insider Ownership Summary of Bvf Partners L P/il

Ticker	Comapny	Transaction Date	Type of Owner
FPRX	Five Prime Therapeutics Inc	2020-10-06	10 percent owner
ELDN	Eledon Pharmaceuticals Inc	2020-10-01	10 percent owner
XOMA	XOMA Royalty Corp	2017-02-10	10 percent owner
		2020-01-01	10 percent owner
		2021-06-16	director & other: See Remarks
		2020-08-18	10 percent owner
		2020-06-18	10 percent owner
		2019-06-19	10 percent owner
		2017-06-09	10 percent owner
		2019-12-09	10 percent owner
		2018-11-16	10 percent owner
		2017-05-01	10 percent owner
		2017-09-19	10 percent owner
		2016-11-30	10 percent owner
		2018-12-04	10 percent owner
		2017-11-28	10 percent owner
		2018-05-30	10 percent owner
		2016-09-08	10 percent owner
		2017-11-17	10 percent owner
		2011-09-06	10 percent owner & other: Indirect Beneficial Owner
		2017-05-08	10 percent owner
		2016-06-23	10 percent owner
		2015-06-10	10 percent owner
		2012-11-16	10 percent owner
		2014-03-25	10 percent owner & other: Indirect Beneficial Owners
		2014-03-21	other: See Explanation of Responses
		2011-10-05	10 percent owner
		2013-11-19	10 percent owner
		2011-10-12	10 percent owner & other: Indirect Beneficial Owner
		2009-12-22	10 percent owner
		2009-12-18	10 percent owner
		2009-10-21	10 percent owner
		2009-09-10	10 percent owner & other: Indirect Beneficial Owners
		2009-05-15	10 percent owner & other: Group Member
		2009-02-03	10 percent owner & other: Indirect Beneficial Owners
		2006-06-06	10 percent owner & other: Indirect Beneficial Owner
		2006-01-12	10 percent owner & other: Indirect Beneficial Owner
		2004-07-08	10 percent owner & other: Indirect Beneficial Owner
		2003-10-27	10 percent owner & other: Indirect Beneficial Owner
		2017-02-10	10 percent owner
		2020-12-18	10 percent owner
		2022-01-25	10 percent owner
		2021-04-22	director & other: See Remarks
		2020-11-18	director & 10 percent owner & other: See Remarks
		2021-12-31	10 percent owner
		2021-10-28	10 percent owner
		2022-04-05	director & 10 percent owner
		2022-06-16	10 percent owner
		2022-07-11	10 percent owner
		2022-12-19	10 percent owner
		2023-02-03	10 percent owner
		2023-11-02	10 percent owner

Bvf Partners L P/il Latest Holdings Summary

Bvf Partners L P/il currently owns a total of 14 stocks. Among these stocks, Bvf Partners L P/il owns 12,965,657 shares of Array BioPharma Inc (ARRY) as of June 25, 2014, with a value of $505 Million and a weighting of 35.88%. Bvf Partners L P/il owns 3,527,700 shares of Neurocrine Biosciences Inc (NBIX) as of October 12, 2011, with a value of $425 Million and a weighting of 30.21%. Bvf Partners L P/il also owns 16,832,292 shares of Arqule Inc (ARQL) as of April 5, 2010, with a value of $337 Million and a weighting of 23.91%. The other 11 stocks ChemoCentryx Inc (CCXI) , Ligand Pharmaceuticals Inc (LGND) , BioCryst Pharmaceuticals Inc (BCRX) , Rigel Pharmaceuticals Inc (RIGL) , Arena Pharmaceuticals Inc (ARNA) , Dynavax Technologies Corp (DVAX) , Curis Inc (CRIS) , Catalyst Biosciences Inc (CBIO) , Capstone Holding Corp (CAPS) , Aeolus Pharmaceuticals Inc (AOLS) , Neurobiological Technologies Inc (NTII) have a combined weighting of 10% among all his current holdings.

Latest Holdings of Bvf Partners L P/il

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
ARRY	Array BioPharma Inc	2014-06-25	12,965,657	38.95	505,012,340
NBIX	Neurocrine Biosciences Inc	2011-10-12	3,527,700	120.54	425,211,320
ARQL	Arqule Inc	2010-04-05	16,832,292	20.00	336,645,840
CCXI	ChemoCentryx Inc	2015-06-10	1,251,914	51.99	65,087,009
LGND	Ligand Pharmaceuticals Inc	2014-03-25	360,300	109.46	39,438,438
BCRX	BioCryst Pharmaceuticals Inc	2003-10-27	1,455,900	7.26	10,562,700
RIGL	Rigel Pharmaceuticals Inc	2013-11-19	696,212	14.42	10,039,377
ARNA	Arena Pharmaceuticals Inc	2004-07-08	99,485	99.99	9,947,505
DVAX	Dynavax Technologies Corp	2009-09-10	427,885	11.92	5,100,389
CRIS	Curis Inc	2009-02-03	142,581	4.21	600,266
CBIO	Catalyst Biosciences Inc	2012-11-16	3,328	7.67	25,524
CAPS	Capstone Holding Corp	2011-09-06	4,610	3.20	14,752
AOLS	Aeolus Pharmaceuticals Inc	2005-11-21	1,870,000	0.00	187
NTII	Neurobiological Technologies Inc	2009-10-21	331,998	0.00	33

Holding Weightings of Bvf Partners L P/il

Bvf Partners L P/il Form 4 Trading Tracker

According to the SEC Form 4 filings, Bvf Partners L P/il has made a total of 0 transactions in Array BioPharma Inc (ARRY) over the past 5 years. The most-recent trade in Array BioPharma Inc is the sale of 0 shares on June 25, 2014, which brought Bvf Partners L P/il around $0.

According to the SEC Form 4 filings, Bvf Partners L P/il has made a total of 0 transactions in Neurocrine Biosciences Inc (NBIX) over the past 5 years. The most-recent trade in Neurocrine Biosciences Inc is the acquisition of 29,500 shares on October 12, 2011, which cost Bvf Partners L P/il around $175,820.

According to the SEC Form 4 filings, Bvf Partners L P/il has made a total of 0 transactions in Arqule Inc (ARQL) over the past 5 years. The most-recent trade in Arqule Inc is the sale of 603,000 shares on April 5, 2010, which brought Bvf Partners L P/il around $4 Million.

More details on Bvf Partners L P/il's insider transactions can be found in the Insider Trading History of Bvf Partners L P/il table.

Insider Trading History of Bvf Partners L P/il

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Bvf Partners L P/il Trading Performance

GuruFocus tracks the stock performance after each of Bvf Partners L P/il's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Bvf Partners L P/il is 16.03%. GuruFocus also compares Bvf Partners L P/il's trading performance to market benchmark return within the same time period. The performance of stocks bought by Bvf Partners L P/il within 3 months outperforms 43 times out of 88 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Bvf Partners L P/il's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Bvf Partners L P/il

Average Return

Average return per transaction

Outperforming Transactions

33 out of 89 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	15.54
Relative Return to S&P 500(%)	15.02

Bvf Partners L P/il Ownership Network

Ownership Network List of Bvf Partners L P/il

No Data

Ownership Network Relation of Bvf Partners L P/il

Bvf Partners L P/il Owned Company Details

What does Five Prime Therapeutics Inc do?

Who are the key executives at Five Prime Therapeutics Inc?

Bvf Partners L P/il is the 10 percent owner of Five Prime Therapeutics Inc. Other key executives at Five Prime Therapeutics Inc include 10 percent owner Biotechnology Value Fund L P , 10 percent owner Bvf Inc/il , and other: See Explanation of Responses Biotechnology Value Fund Ii Lp .

Five Prime Therapeutics Inc (FPRX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Five Prime Therapeutics Inc (FPRX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Five Prime Therapeutics Inc (FPRX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Five Prime Therapeutics Inc (FPRX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Five Prime Therapeutics Inc Insider Transactions

No Available Data

What does Eledon Pharmaceuticals Inc do?

Who are the key executives at Eledon Pharmaceuticals Inc?

Bvf Partners L P/il is the 10 percent owner of Eledon Pharmaceuticals Inc. Other key executives at Eledon Pharmaceuticals Inc include other: See Explanation of Responses Biotechnology Value Fund L P , director & See Remarks Steven Perrin , and director & Chief Executive Officer David-alexandre C Gros .

Eledon Pharmaceuticals Inc (ELDN) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Eledon Pharmaceuticals Inc (ELDN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Eledon Pharmaceuticals Inc (ELDN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Eledon Pharmaceuticals Inc (ELDN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Eledon Pharmaceuticals Inc Insider Transactions

No Available Data

What does XOMA Royalty Corp do?

Who are the key executives at XOMA Royalty Corp?

Bvf Partners L P/il is the 10 percent owner of XOMA Royalty Corp. Other key executives at XOMA Royalty Corp include Chief Investment Officer Bradley Sitko , director & Interim CEO Owen Hughes , and other: See Explanation of Responses Biotechnology Value Fund L P .

XOMA Royalty Corp (XOMA) Insider Trades Summary

Over the past 18 months, Bvf Partners L P/il made no insider transaction in XOMA Royalty Corp (XOMA). Other recent insider transactions involving XOMA Royalty Corp (XOMA) include a net purchase of 9,100 shares made by Bradley Sitko , and a net purchase of 5,500 shares made by Owen Hughes .

In summary, during the past 3 months, insiders sold 0 shares of XOMA Royalty Corp (XOMA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of XOMA Royalty Corp (XOMA) were sold and 14,600 shares were bought by its insiders, resulting in a net purchase of 14,600 shares.

XOMA Royalty Corp (XOMA)'s detailed insider trading history can be found in Insider Trading Tracker table.

XOMA Royalty Corp Insider Transactions

No Available Data

What does Merus NV do?

Who are the key executives at Merus NV?

Bvf Partners L P/il is the 10 percent owner of Merus NV. Other key executives at Merus NV include Chief Accounting Officer Harry Shuman , EVP & General Counsel Peter B. Silverman , and director & President & CEO & PFO Sven Ante Lundberg .

Merus NV (MRUS) Insider Trades Summary

Over the past 18 months, Bvf Partners L P/il made no insider transaction in Merus NV (MRUS). Other recent insider transactions involving Merus NV (MRUS) include a net sale of 20,815 shares made by Harry Shuman , and a net sale of 94,386 shares made by Peter B. Silverman .

In summary, during the past 3 months, insiders sold 5,000 shares of Merus NV (MRUS) in total and bought 0 shares, with a net sale of 5,000 shares. During the past 18 months, 115,201 shares of Merus NV (MRUS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 115,201 shares.

Merus NV (MRUS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Merus NV Insider Transactions

No Available Data

What does Kymera Therapeutics Inc do?

Who are the key executives at Kymera Therapeutics Inc?

Bvf Partners L P/il is the director & other: See Remarks of Kymera Therapeutics Inc. Other key executives at Kymera Therapeutics Inc include Chief Medical Officer Jared Gollob , Chief Operating Officer Jeremy G Chadwick , and 10 percent owner Atlas Venture Fund X, L.p. .

Kymera Therapeutics Inc (KYMR) Insider Trades Summary

Over the past 18 months, Bvf Partners L P/il made no insider transaction in Kymera Therapeutics Inc (KYMR). Other recent insider transactions involving Kymera Therapeutics Inc (KYMR) include a net sale of 961,800 shares made by Bruce Booth , a net sale of 89,481 shares made by Jared Gollob , and a net sale of 20,000 shares made by Jeffrey W. Albers .

In summary, during the past 3 months, insiders sold 18,500 shares of Kymera Therapeutics Inc (KYMR) in total and bought 1 shares, with a net sale of 18,499 shares. During the past 18 months, 1,456,442 shares of Kymera Therapeutics Inc (KYMR) were sold and 414,106 shares were bought by its insiders, resulting in a net sale of 1,042,336 shares.

Kymera Therapeutics Inc (KYMR)'s detailed insider trading history can be found in Insider Trading Tracker table.

Kymera Therapeutics Inc Insider Transactions

No Available Data

What does Principia Biopharma Inc do?

Who are the key executives at Principia Biopharma Inc?

Bvf Partners L P/il is the 10 percent owner of Principia Biopharma Inc. Other key executives at Principia Biopharma Inc include director & President & CEO Martin Babler , Chief Development Officer Stefani Wolff , and Chief Scientific Officer David M Goldstein .

Principia Biopharma Inc (PRNB) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Principia Biopharma Inc (PRNB) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Principia Biopharma Inc (PRNB) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Principia Biopharma Inc (PRNB)'s detailed insider trading history can be found in Insider Trading Tracker table.

Principia Biopharma Inc Insider Transactions

No Available Data

What does IDEAYA Biosciences Inc do?

Who are the key executives at IDEAYA Biosciences Inc?

Bvf Partners L P/il is the 10 percent owner of IDEAYA Biosciences Inc. Other key executives at IDEAYA Biosciences Inc include SVP & Chief Scientific Officer Michael Anthony White , director & President and CEO Yujiro S Hata , and See Remarks Briseno Andres Ruiz .

IDEAYA Biosciences Inc (IDYA) Insider Trades Summary

Over the past 18 months, Bvf Partners L P/il made no insider transaction in IDEAYA Biosciences Inc (IDYA). Other recent insider transactions involving IDEAYA Biosciences Inc (IDYA) include a net sale of 38,970 shares made by Jason Throne , a net sale of 425,000 shares made by Yujiro S Hata , and a net sale of 10,000 shares made by Briseno Andres Ruiz .

In summary, during the past 3 months, insiders sold 0 shares of IDEAYA Biosciences Inc (IDYA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 514,970 shares of IDEAYA Biosciences Inc (IDYA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 514,970 shares.

IDEAYA Biosciences Inc (IDYA)'s detailed insider trading history can be found in Insider Trading Tracker table.

IDEAYA Biosciences Inc Insider Transactions

No Available Data

What does Calithera Biosciences Inc do?

Who are the key executives at Calithera Biosciences Inc?

Bvf Partners L P/il is the 10 percent owner of Calithera Biosciences Inc. Other key executives at Calithera Biosciences Inc include director & 10 percent owner Deepika Pakianathan , 10 percent owner Takeda Ventures, Inc. , and SR. VP & CLINICAL DEVELOPMENT Keith Orford .

Calithera Biosciences Inc (CALA) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Calithera Biosciences Inc (CALA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Calithera Biosciences Inc (CALA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Calithera Biosciences Inc (CALA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Calithera Biosciences Inc Insider Transactions

No Available Data

What does CTI BioPharma Corp do?

Who are the key executives at CTI BioPharma Corp?

Bvf Partners L P/il is the 10 percent owner of CTI BioPharma Corp. Other key executives at CTI BioPharma Corp include EVP & Chief Commercial Officer James K Fong , director & President and CEO Adam R Craig , and EVP & Chief Financial Officer David Kirske .

CTI BioPharma Corp (CTIC) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of CTI BioPharma Corp (CTIC) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of CTI BioPharma Corp (CTIC) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

CTI BioPharma Corp (CTIC)'s detailed insider trading history can be found in Insider Trading Tracker table.

CTI BioPharma Corp Insider Transactions

No Available Data

What does Cytokinetics Inc do?

Who are the key executives at Cytokinetics Inc?

Bvf Partners L P/il is the 10 percent owner of Cytokinetics Inc. Other key executives at Cytokinetics Inc include EVP & Corp. Development & CBO Robert I Blum , SVP Research & Early Dev Fady Ibraham Malik , and VP & Chief Accounting Officer Robert Wong .

Cytokinetics Inc (CYTK) Insider Trades Summary

Over the past 18 months, Bvf Partners L P/il made no insider transaction in Cytokinetics Inc (CYTK). Other recent insider transactions involving Cytokinetics Inc (CYTK) include a net sale of 351,000 shares made by Robert I Blum , a net sale of 194,094 shares made by Fady Ibraham Malik , and a net sale of 40,000 shares made by B Lynne Parshall .

In summary, during the past 3 months, insiders sold 107,136 shares of Cytokinetics Inc (CYTK) in total and bought 0 shares, with a net sale of 107,136 shares. During the past 18 months, 651,596 shares of Cytokinetics Inc (CYTK) were sold and 0 shares were bought by its insiders, resulting in a net sale of 651,596 shares.

Cytokinetics Inc (CYTK)'s detailed insider trading history can be found in Insider Trading Tracker table.

Cytokinetics Inc Insider Transactions

No Available Data

What does Pieris Pharmaceuticals Inc do?

Who are the key executives at Pieris Pharmaceuticals Inc?

Bvf Partners L P/il is the 10 percent owner of Pieris Pharmaceuticals Inc. Other key executives at Pieris Pharmaceuticals Inc include 10 percent owner Bvf Gp Holdings Llc , 10 percent owner Bvf I Gp Llc , and other: See Explanation of Responses Bvf Ii Gp Llc .

Pieris Pharmaceuticals Inc (PIRS) Insider Trades Summary

Over the past 18 months, Bvf Partners L P/il made no insider transaction in Pieris Pharmaceuticals Inc (PIRS). Other recent insider transactions involving Pieris Pharmaceuticals Inc (PIRS) include a net purchase of 10,000 shares made by Christopher P Kiritsy , and a net purchase of 6,000 shares made by .

In summary, during the past 3 months, insiders sold 0 shares of Pieris Pharmaceuticals Inc (PIRS) in total and bought 6,000 shares, with a net purchase of 6,000 shares. During the past 18 months, 0 shares of Pieris Pharmaceuticals Inc (PIRS) were sold and 6,125 shares were bought by its insiders, resulting in a net purchase of 6,125 shares.

Pieris Pharmaceuticals Inc (PIRS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Pieris Pharmaceuticals Inc Insider Transactions

No Available Data

What does GlycoMimetics Inc do?

Who are the key executives at GlycoMimetics Inc?

Bvf Partners L P/il is the 10 percent owner of GlycoMimetics Inc. Other key executives at GlycoMimetics Inc include 10 percent owner Invus Public Equities, L.p. , Chief Medical Officer Edwin Rock , and CFO Brian M. Hahn .

GlycoMimetics Inc (GLYC) Insider Trades Summary

Over the past 18 months, Bvf Partners L P/il made no insider transaction in GlycoMimetics Inc (GLYC). Other recent insider transactions involving GlycoMimetics Inc (GLYC) include a net sale of 2,271,499 shares made by Invus Public Equities, L.p. , a net purchase of 370,403 shares made by Edwin Rock , and a net purchase of 13,800 shares made by Brian M. Hahn .

In summary, during the past 3 months, insiders sold 542,616 shares of GlycoMimetics Inc (GLYC) in total and bought 0 shares, with a net sale of 542,616 shares. During the past 18 months, 2,275,199 shares of GlycoMimetics Inc (GLYC) were sold and 431,403 shares were bought by its insiders, resulting in a net sale of 1,843,796 shares.

GlycoMimetics Inc (GLYC)'s detailed insider trading history can be found in Insider Trading Tracker table.

GlycoMimetics Inc Insider Transactions

No Available Data

What does Concert Pharmaceuticals Inc do?

Who are the key executives at Concert Pharmaceuticals Inc?

Bvf Partners L P/il is the 10 percent owner of Concert Pharmaceuticals Inc. Other key executives at Concert Pharmaceuticals Inc include Chief Development Officer James V Cassella , CFO & PFO Marc A. Becker , and Chief Operating Officer Nancy Stuart .

Concert Pharmaceuticals Inc (CNCE) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Concert Pharmaceuticals Inc (CNCE) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Concert Pharmaceuticals Inc (CNCE) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Concert Pharmaceuticals Inc (CNCE)'s detailed insider trading history can be found in Insider Trading Tracker table.

Concert Pharmaceuticals Inc Insider Transactions

No Available Data

What does Infinity Pharmaceuticals Inc do?

Who are the key executives at Infinity Pharmaceuticals Inc?

Bvf Partners L P/il is the 10 percent owner of Infinity Pharmaceuticals Inc. Other key executives at Infinity Pharmaceuticals Inc include director & President & CEO Adelene Q Perkins , Chief Scientific Officer Stephane Peluso , and Chief Medical Officer Robert Jr. Ilaria .

Infinity Pharmaceuticals Inc (INFIQ) Insider Trades Summary

Over the past 18 months, Bvf Partners L P/il made no insider transaction in Infinity Pharmaceuticals Inc (INFIQ). Other recent insider transactions involving Infinity Pharmaceuticals Inc (INFIQ) include a net sale of 410,196 shares made by Adelene Q Perkins ,

In summary, during the past 3 months, insiders sold 0 shares of Infinity Pharmaceuticals Inc (INFIQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 410,196 shares of Infinity Pharmaceuticals Inc (INFIQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 410,196 shares.

Infinity Pharmaceuticals Inc (INFIQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Infinity Pharmaceuticals Inc Insider Transactions

No Available Data

What does Immune Design Corp do?

Who are the key executives at Immune Design Corp?

Bvf Partners L P/il is the 10 percent owner of Immune Design Corp. Other key executives at Immune Design Corp include 10 percent owner & other: General Partner Column Group Gp, Lp , 10 percent owner Column Group L P , and 10 percent owner & other: General Partner Ponoi Management, Llc .

Immune Design Corp (IMDZ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Immune Design Corp (IMDZ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Immune Design Corp (IMDZ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Immune Design Corp (IMDZ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Immune Design Corp Insider Transactions

No Available Data

What does Syndax Pharmaceuticals Inc do?

Who are the key executives at Syndax Pharmaceuticals Inc?

Bvf Partners L P/il is the 10 percent owner of Syndax Pharmaceuticals Inc. Other key executives at Syndax Pharmaceuticals Inc include Chief Financial Officer Keith A. Goldan , director & Chief Executive Officer Briggs Morrison , and President & Head of R&D Neil Gallagher .

Syndax Pharmaceuticals Inc (SNDX) Insider Trades Summary

Over the past 18 months, Bvf Partners L P/il made no insider transaction in Syndax Pharmaceuticals Inc (SNDX). Other recent insider transactions involving Syndax Pharmaceuticals Inc (SNDX) include a net sale of 211,420 shares made by Briggs Morrison , a net purchase of 673 shares made by Keith A. Goldan , and a net sale of 83,000 shares made by William Meury .

In summary, during the past 3 months, insiders sold 0 shares of Syndax Pharmaceuticals Inc (SNDX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 294,997 shares of Syndax Pharmaceuticals Inc (SNDX) were sold and 1,250 shares were bought by its insiders, resulting in a net sale of 293,747 shares.

Syndax Pharmaceuticals Inc (SNDX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Syndax Pharmaceuticals Inc Insider Transactions

No Available Data

What does Arqule Inc do?

Who are the key executives at Arqule Inc?

Bvf Partners L P/il is the 10 percent owner of Arqule Inc. Other key executives at Arqule Inc include director & Chief Executive Officer Paolo Pucci , CFO and Treasurer Marc Schegerin , and See Remarks Brian Schwartz .

Arqule Inc (ARQL) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Arqule Inc (ARQL) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Arqule Inc (ARQL) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Arqule Inc (ARQL)'s detailed insider trading history can be found in Insider Trading Tracker table.

Arqule Inc Insider Transactions

No Available Data

What does Xenon Pharmaceuticals Inc do?

Who are the key executives at Xenon Pharmaceuticals Inc?

Bvf Partners L P/il is the 10 percent owner of Xenon Pharmaceuticals Inc. Other key executives at Xenon Pharmaceuticals Inc include SVP Bus. & Corp. Development Sherrington Robin , director & PRESIDENT & CEO Ian Mortimer , and Chief Medical Officer Christopher John Kenney .

Xenon Pharmaceuticals Inc (XENE) Insider Trades Summary

Over the past 18 months, Bvf Partners L P/il made no insider transaction in Xenon Pharmaceuticals Inc (XENE). Other recent insider transactions involving Xenon Pharmaceuticals Inc (XENE) include a net sale of 26,576 shares made by Gary Patou , a net sale of 131,245 shares made by Simon N. Pimstone , and a net sale of 31,655 shares made by Ian Mortimer .

In summary, during the past 3 months, insiders sold 0 shares of Xenon Pharmaceuticals Inc (XENE) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 236,705 shares of Xenon Pharmaceuticals Inc (XENE) were sold and 0 shares were bought by its insiders, resulting in a net sale of 236,705 shares.

Xenon Pharmaceuticals Inc (XENE)'s detailed insider trading history can be found in Insider Trading Tracker table.

Xenon Pharmaceuticals Inc Insider Transactions

No Available Data

What does Regulus Therapeutics Inc do?

Who are the key executives at Regulus Therapeutics Inc?

Bvf Partners L P/il is the 10 percent owner of Regulus Therapeutics Inc. Other key executives at Regulus Therapeutics Inc include Sr. VP & General Counsel Christopher Ray Aker , Chief Operating Officer Joseph P Hagan , and Chief Financial Officer Crispina Calsada .

Regulus Therapeutics Inc (RGLS) Insider Trades Summary

Over the past 18 months, Bvf Partners L P/il made no insider transaction in Regulus Therapeutics Inc (RGLS). Other recent insider transactions involving Regulus Therapeutics Inc (RGLS) include a net sale of 14,580 shares made by Joseph P Hagan , a net sale of 5,468 shares made by Crispina Calsada , and a net sale of 5,468 shares made by Christopher Ray Aker .

In summary, during the past 3 months, insiders sold 0 shares of Regulus Therapeutics Inc (RGLS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 25,516 shares of Regulus Therapeutics Inc (RGLS) were sold and 4,000 shares were bought by its insiders, resulting in a net sale of 21,516 shares.

Regulus Therapeutics Inc (RGLS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Regulus Therapeutics Inc Insider Transactions

No Available Data

What does Capstone Holding Corp do?

Who are the key executives at Capstone Holding Corp?

Bvf Partners L P/il is the 10 percent owner & other: Indirect Beneficial Owner of Capstone Holding Corp. Other key executives at Capstone Holding Corp include other: See Remarks Alimco Financial Corp , 10 percent owner Neil S Subin , and 10 percent owner Miller Lloyd I Iii .

Capstone Holding Corp (CAPS) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Capstone Holding Corp (CAPS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Capstone Holding Corp (CAPS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Capstone Holding Corp (CAPS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Capstone Holding Corp Insider Transactions

No Available Data

What does Alpine Immune Sciences Inc do?

Who are the key executives at Alpine Immune Sciences Inc?

Bvf Partners L P/il is the 10 percent owner of Alpine Immune Sciences Inc. Other key executives at Alpine Immune Sciences Inc include Senior VP and CFO James Paul Rickey , director & Executive Chairman and CEO Mitchell Gold , and director & 10 percent owner Xiangmin Cui .

Alpine Immune Sciences Inc (ALPN) Insider Trades Summary

Over the past 18 months, Bvf Partners L P/il made no insider transaction in Alpine Immune Sciences Inc (ALPN). Other recent insider transactions involving Alpine Immune Sciences Inc (ALPN) include a net sale of 281,514 shares made by James Paul Rickey , a net sale of 213,302 shares made by Mitchell Gold , and a net sale of 1,546,347 shares made by Peter A. Thompson .

In summary, during the past 3 months, insiders sold 0 shares of Alpine Immune Sciences Inc (ALPN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 3,587,529 shares of Alpine Immune Sciences Inc (ALPN) were sold and 750,000 shares were bought by its insiders, resulting in a net sale of 2,837,529 shares.

Alpine Immune Sciences Inc (ALPN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Alpine Immune Sciences Inc Insider Transactions

No Available Data

What does Cascadian Therapeutics Inc do?

Who are the key executives at Cascadian Therapeutics Inc?

Bvf Partners L P/il is the 10 percent owner of Cascadian Therapeutics Inc. Other key executives at Cascadian Therapeutics Inc include 10 percent owner Nea Partners 15, L.p. , 10 percent owner New Enterprise Associates 15, L.p. , and 10 percent owner Jon Sakoda .

Cascadian Therapeutics Inc (CASC) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Cascadian Therapeutics Inc (CASC) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Cascadian Therapeutics Inc (CASC) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Cascadian Therapeutics Inc (CASC)'s detailed insider trading history can be found in Insider Trading Tracker table.

Cascadian Therapeutics Inc Insider Transactions

No Available Data

What does ChemoCentryx Inc do?

Who are the key executives at ChemoCentryx Inc?

Bvf Partners L P/il is the 10 percent owner of ChemoCentryx Inc. Other key executives at ChemoCentryx Inc include SVP Finance & CFO & Secretary Susan M Kanaya , director & 10 percent owner & President & CEO and Director Thomas J. Schall , and SVP & Finance & Acctg Officer Yi Ching Yau .

ChemoCentryx Inc (CCXI) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of ChemoCentryx Inc (CCXI) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of ChemoCentryx Inc (CCXI) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

ChemoCentryx Inc (CCXI)'s detailed insider trading history can be found in Insider Trading Tracker table.

ChemoCentryx Inc Insider Transactions

No Available Data

What does Catalyst Biosciences Inc do?

Who are the key executives at Catalyst Biosciences Inc?

Bvf Partners L P/il is the 10 percent owner of Catalyst Biosciences Inc. Other key executives at Catalyst Biosciences Inc include director & Chief Executive Officer Charles C Wu , director & President Songjiang Ma , and Chief Operating Officer Weiguo Ye .

Catalyst Biosciences Inc (CBIO) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Catalyst Biosciences Inc (CBIO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Catalyst Biosciences Inc (CBIO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Catalyst Biosciences Inc (CBIO)'s detailed insider trading history can be found in Insider Trading Tracker table.

Catalyst Biosciences Inc Insider Transactions

No Available Data

What does Ligand Pharmaceuticals Inc do?

Who are the key executives at Ligand Pharmaceuticals Inc?

Bvf Partners L P/il is the 10 percent owner & other: Indirect Beneficial Owners of Ligand Pharmaceuticals Inc. Other key executives at Ligand Pharmaceuticals Inc include CHIEF LEGAL OFFICER & Andrew Reardon , VP & Finance and CFO Matthew E Korenberg , and Chief Financial Officer Octavio Espinoza .

Ligand Pharmaceuticals Inc (LGND) Insider Trades Summary

Over the past 18 months, Bvf Partners L P/il made no insider transaction in Ligand Pharmaceuticals Inc (LGND). Other recent insider transactions involving Ligand Pharmaceuticals Inc (LGND) include a net sale of 70,748 shares made by Matthew E Korenberg , a net sale of 14,708 shares made by Octavio Espinoza , and a net sale of 13,500 shares made by Andrew Reardon .

In summary, during the past 3 months, insiders sold 57,925 shares of Ligand Pharmaceuticals Inc (LGND) in total and bought 2,500 shares, with a net sale of 55,425 shares. During the past 18 months, 119,043 shares of Ligand Pharmaceuticals Inc (LGND) were sold and 6,500 shares were bought by its insiders, resulting in a net sale of 112,543 shares.

Ligand Pharmaceuticals Inc (LGND)'s detailed insider trading history can be found in Insider Trading Tracker table.

Ligand Pharmaceuticals Inc Insider Transactions

No Available Data

What does Regado Biosciences Inc do?

Who are the key executives at Regado Biosciences Inc?

Bvf Partners L P/il is the other: See Explanation of Responses of Regado Biosciences Inc. Other key executives at Regado Biosciences Inc include 10 percent owner Associates Domain , Chief Medical Officer Eric Lefebvre , and Chief Financial Officer Christopher Peetz .

Regado Biosciences Inc (RGDO) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Regado Biosciences Inc (RGDO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Regado Biosciences Inc (RGDO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Regado Biosciences Inc (RGDO)'s detailed insider trading history can be found in Insider Trading Tracker table.

Regado Biosciences Inc Insider Transactions

No Available Data

What does Palatin Technologies Inc do?

Who are the key executives at Palatin Technologies Inc?

Bvf Partners L P/il is the 10 percent owner of Palatin Technologies Inc. Other key executives at Palatin Technologies Inc include Executive Vice President & CFO Stephen T Wills , director & President and CEO Carl Spana , and director & Exec. VP Research and Devel. Perry B Molinoff .

Palatin Technologies Inc (PTN) Insider Trades Summary

Over the past 18 months, Bvf Partners L P/il made no insider transaction in Palatin Technologies Inc (PTN). Other recent insider transactions involving Palatin Technologies Inc (PTN) include a net sale of 9,997 shares made by Stephen T Wills , a net sale of 5,700 shares made by Deveer Robert K Jr , and a net sale of 200 shares made by Alan W Dunton .

In summary, during the past 3 months, insiders sold 0 shares of Palatin Technologies Inc (PTN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 21,897 shares of Palatin Technologies Inc (PTN) were sold and 6,000 shares were bought by its insiders, resulting in a net sale of 15,897 shares.

Palatin Technologies Inc (PTN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Palatin Technologies Inc Insider Transactions

No Available Data

What does Rigel Pharmaceuticals Inc do?

Who are the key executives at Rigel Pharmaceuticals Inc?

Bvf Partners L P/il is the 10 percent owner of Rigel Pharmaceuticals Inc. Other key executives at Rigel Pharmaceuticals Inc include EVP & Chief Financial Officer Dean L Schorno , Sr VP of Bus Dev and Com Ops Raul R Rodriguez , and EVP & Chief Commercial Officer David A Santos .

Rigel Pharmaceuticals Inc (RIGL) Insider Trades Summary

Over the past 18 months, Bvf Partners L P/il made no insider transaction in Rigel Pharmaceuticals Inc (RIGL). Other recent insider transactions involving Rigel Pharmaceuticals Inc (RIGL) include a net sale of 52,894 shares made by Raul R Rodriguez , a net sale of 14,519 shares made by David A Santos , and a net sale of 12,628 shares made by Dean L Schorno .

In summary, during the past 3 months, insiders sold 0 shares of Rigel Pharmaceuticals Inc (RIGL) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 8,004 shares of Rigel Pharmaceuticals Inc (RIGL) were sold and 0 shares were bought by its insiders, resulting in a net sale of 8,004 shares.

Rigel Pharmaceuticals Inc (RIGL)'s detailed insider trading history can be found in Insider Trading Tracker table.

Rigel Pharmaceuticals Inc Insider Transactions

No Available Data

What does Neurocrine Biosciences Inc do?

Who are the key executives at Neurocrine Biosciences Inc?

Bvf Partners L P/il is the 10 percent owner & other: Indirect Beneficial Owner of Neurocrine Biosciences Inc. Other key executives at Neurocrine Biosciences Inc include Chief Corp. Affairs Officer David W. Boyer , Chief Regulatory Officer Ingrid Delaet , and Chief Financial Officer Matt Abernethy .

Neurocrine Biosciences Inc (NBIX) Insider Trades Summary

Over the past 18 months, Bvf Partners L P/il made no insider transaction in Neurocrine Biosciences Inc (NBIX). Other recent insider transactions involving Neurocrine Biosciences Inc (NBIX) include a net sale of 32,776 shares made by Ingrid Delaet , a net sale of 58,181 shares made by Darin Lippoldt , and a net sale of 55,568 shares made by Julie Cooke .

In summary, during the past 3 months, insiders sold 52,092 shares of Neurocrine Biosciences Inc (NBIX) in total and bought 0 shares, with a net sale of 52,092 shares. During the past 18 months, 993,959 shares of Neurocrine Biosciences Inc (NBIX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 993,959 shares.

Neurocrine Biosciences Inc (NBIX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Neurocrine Biosciences Inc Insider Transactions

No Available Data

What does EPIRUS Biopharmaceuticals Inc do?

Who are the key executives at EPIRUS Biopharmaceuticals Inc?

Bvf Partners L P/il is the 10 percent owner of EPIRUS Biopharmaceuticals Inc. Other key executives at EPIRUS Biopharmaceuticals Inc include Chief Business Officer Vincent Aurentz , Chief Financial Officer Thomas A. Shea , and director & Chief Executive Officer Amit Munshi .

EPIRUS Biopharmaceuticals Inc (EPRSQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of EPIRUS Biopharmaceuticals Inc (EPRSQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of EPIRUS Biopharmaceuticals Inc (EPRSQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

EPIRUS Biopharmaceuticals Inc (EPRSQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

EPIRUS Biopharmaceuticals Inc Insider Transactions

No Available Data

What does MediciNova Inc do?

Who are the key executives at MediciNova Inc?

Bvf Partners L P/il is the 10 percent owner of MediciNova Inc. Other key executives at MediciNova Inc include Chief Financial Officer Jason J Kruger , Chief Financial Officer Douglas Paulin , and Chief Scientific Officer Gaeta Federico C.a. .

MediciNova Inc (MNOV) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of MediciNova Inc (MNOV) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of MediciNova Inc (MNOV) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

MediciNova Inc (MNOV)'s detailed insider trading history can be found in Insider Trading Tracker table.

MediciNova Inc Insider Transactions

No Available Data

What does Neurobiological Technologies Inc do?

Who are the key executives at Neurobiological Technologies Inc?

Bvf Partners L P/il is the 10 percent owner of Neurobiological Technologies Inc. Other key executives at Neurobiological Technologies Inc include 10 percent owner Ariel Warszawski , 10 percent owner Ryan Heslop , and 10 percent owner Firefly Management Co Gp, Llc .

Neurobiological Technologies Inc (NTII) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Neurobiological Technologies Inc (NTII) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Neurobiological Technologies Inc (NTII) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Neurobiological Technologies Inc (NTII)'s detailed insider trading history can be found in Insider Trading Tracker table.

Neurobiological Technologies Inc Insider Transactions

No Available Data

What does Dynavax Technologies Corp do?

Who are the key executives at Dynavax Technologies Corp?

Bvf Partners L P/il is the 10 percent owner & other: Indirect Beneficial Owners of Dynavax Technologies Corp. Other key executives at Dynavax Technologies Corp include Principal Accounting Officer Justin Burgess , Chief Medical Officer and VP Robert Janssen , and Senior Vice President David F Novack .

Dynavax Technologies Corp (DVAX) Insider Trades Summary

Over the past 18 months, Bvf Partners L P/il made no insider transaction in Dynavax Technologies Corp (DVAX). Other recent insider transactions involving Dynavax Technologies Corp (DVAX) include a net sale of 169,000 shares made by David F Novack , a net sale of 46,327 shares made by Robert Janssen , and a net sale of 3,000,000 shares made by Hack Andrew A. F. .

In summary, during the past 3 months, insiders sold 0 shares of Dynavax Technologies Corp (DVAX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 3,247,529 shares of Dynavax Technologies Corp (DVAX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 3,247,529 shares.

Dynavax Technologies Corp (DVAX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Dynavax Technologies Corp Insider Transactions

No Available Data

What does Repligen Corp do?

Who are the key executives at Repligen Corp?

Bvf Partners L P/il is the 10 percent owner & other: Group Member of Repligen Corp. Other key executives at Repligen Corp include director & Chief Executive Officer Anthony Hunt , Senior VP & R&D Ralf Kuriyel , and SVP & Global Operations & IT James Bylund .

Repligen Corp (RGEN) Insider Trades Summary

Over the past 18 months, Bvf Partners L P/il made no insider transaction in Repligen Corp (RGEN). Other recent insider transactions involving Repligen Corp (RGEN) include a net sale of 56,970 shares made by Anthony Hunt , a net sale of 15,130 shares made by Ralf Kuriyel , and a net purchase of 3,115 shares made by Martin D Madaus .

In summary, during the past 3 months, insiders sold 22,191 shares of Repligen Corp (RGEN) in total and bought 0 shares, with a net sale of 22,191 shares. During the past 18 months, 84,111 shares of Repligen Corp (RGEN) were sold and 6,315 shares were bought by its insiders, resulting in a net sale of 77,796 shares.

Repligen Corp (RGEN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Repligen Corp Insider Transactions

No Available Data

What does Curis Inc do?

Who are the key executives at Curis Inc?

Bvf Partners L P/il is the 10 percent owner & other: Indirect Beneficial Owners of Curis Inc. Other key executives at Curis Inc include CDO Jonathan B. Zung , CFO Diantha Duvall , and Head of Research & Development Robert Martell .

Curis Inc (CRIS) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Curis Inc (CRIS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Curis Inc (CRIS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Curis Inc (CRIS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Curis Inc Insider Transactions

No Available Data

What does Aeolus Pharmaceuticals Inc do?

Who are the key executives at Aeolus Pharmaceuticals Inc?

Bvf Partners L P/il is the 10 percent owner & other: Indirect Beneficial Owner of Aeolus Pharmaceuticals Inc. Other key executives at Aeolus Pharmaceuticals Inc include President and CEO John L Mcmanus , Chief Financial Officer Russell Skibsted , and 10 percent owner Mark Lappe .

Aeolus Pharmaceuticals Inc (AOLS) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Aeolus Pharmaceuticals Inc (AOLS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Aeolus Pharmaceuticals Inc (AOLS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Aeolus Pharmaceuticals Inc (AOLS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Aeolus Pharmaceuticals Inc Insider Transactions

No Available Data

What does AMAG Pharmaceuticals Inc do?

Who are the key executives at AMAG Pharmaceuticals Inc?

Bvf Partners L P/il is the 10 percent owner & other: Indirect Beneficial Owner of AMAG Pharmaceuticals Inc. Other key executives at AMAG Pharmaceuticals Inc include 10 percent owner Camber Capital Management Lp , Chief Operating Officer Anthony Casciano , and Interim CFO Brian Piekos .

AMAG Pharmaceuticals Inc (AMAG) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of AMAG Pharmaceuticals Inc (AMAG) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of AMAG Pharmaceuticals Inc (AMAG) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

AMAG Pharmaceuticals Inc (AMAG)'s detailed insider trading history can be found in Insider Trading Tracker table.

AMAG Pharmaceuticals Inc Insider Transactions

No Available Data

What does Arena Pharmaceuticals Inc do?

Who are the key executives at Arena Pharmaceuticals Inc?

Bvf Partners L P/il is the 10 percent owner & other: Indirect Beneficial Owner of Arena Pharmaceuticals Inc. Other key executives at Arena Pharmaceuticals Inc include director & President and CEO Amit Munshi , EVP & Chief Commercial Officer Robert Lisicki , and Executive VP and CBO Vincent Aurentz .

Arena Pharmaceuticals Inc (ARNA) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Arena Pharmaceuticals Inc (ARNA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Arena Pharmaceuticals Inc (ARNA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Arena Pharmaceuticals Inc (ARNA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Arena Pharmaceuticals Inc Insider Transactions

No Available Data

What does BioCryst Pharmaceuticals Inc do?

Who are the key executives at BioCryst Pharmaceuticals Inc?

Bvf Partners L P/il is the 10 percent owner & other: Indirect Beneficial Owner of BioCryst Pharmaceuticals Inc. Other key executives at BioCryst Pharmaceuticals Inc include Chief Financial Officer Anthony Doyle , Vice President and CCO Charles K Gayer , and VP & General Counsel & Corp Sec Alane P Barnes .

BioCryst Pharmaceuticals Inc (BCRX) Insider Trades Summary

Over the past 18 months, Bvf Partners L P/il made no insider transaction in BioCryst Pharmaceuticals Inc (BCRX). Other recent insider transactions involving BioCryst Pharmaceuticals Inc (BCRX) include a net sale of 8,689 shares made by Machelle Sanders , a net sale of 7,866 shares made by Nancy J Hutson , and a net purchase of 36,300 shares made by Anthony Doyle .

In summary, during the past 3 months, insiders sold 0 shares of BioCryst Pharmaceuticals Inc (BCRX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 36,853 shares of BioCryst Pharmaceuticals Inc (BCRX) were sold and 183,601 shares were bought by its insiders, resulting in a net purchase of 146,748 shares.

BioCryst Pharmaceuticals Inc (BCRX)'s detailed insider trading history can be found in Insider Trading Tracker table.

BioCryst Pharmaceuticals Inc Insider Transactions

No Available Data

What does XOMA Royalty Corp do?

Who are the key executives at XOMA Royalty Corp?

XOMA Royalty Corp (XOMAO.PFD) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of XOMA Royalty Corp (XOMAO.PFD) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of XOMA Royalty Corp (XOMAO.PFD) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

XOMA Royalty Corp (XOMAO.PFD)'s detailed insider trading history can be found in Insider Trading Tracker table.

XOMA Royalty Corp Insider Transactions

No Available Data

What does CytomX Therapeutics Inc do?

Who are the key executives at CytomX Therapeutics Inc?

Bvf Partners L P/il is the 10 percent owner of CytomX Therapeutics Inc. Other key executives at CytomX Therapeutics Inc include SVP & Chief Scientific Officer Marcia Belvin , SVP & Finance and Accounting Christopher Ogden , and Chief Financial Officer Jeffrey B Landau .

CytomX Therapeutics Inc (CTMX) Insider Trades Summary

Over the past 18 months, Bvf Partners L P/il made no insider transaction in CytomX Therapeutics Inc (CTMX). Other recent insider transactions involving CytomX Therapeutics Inc (CTMX) include a net sale of 62,273 shares made by Sean A. Mccarthy , a net sale of 25,172 shares made by Marcia Belvin , and a net sale of 19,012 shares made by Lloyd A Rowland .

In summary, during the past 3 months, insiders sold 28,425 shares of CytomX Therapeutics Inc (CTMX) in total and bought 0 shares, with a net sale of 28,425 shares. During the past 18 months, 132,341 shares of CytomX Therapeutics Inc (CTMX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 132,341 shares.

CytomX Therapeutics Inc (CTMX)'s detailed insider trading history can be found in Insider Trading Tracker table.

CytomX Therapeutics Inc Insider Transactions

No Available Data

What does Verastem Inc do?

Who are the key executives at Verastem Inc?

Bvf Partners L P/il is the 10 percent owner of Verastem Inc. Other key executives at Verastem Inc include Vice President of Finance Daniel Calkins , Chief Operating Officer Dan Paterson , and Chief Financial Officer Robert E. Gagnon .

Verastem Inc (VSTM) Insider Trades Summary

Over the past 18 months, Bvf Partners L P/il made no insider transaction in Verastem Inc (VSTM). Other recent insider transactions involving Verastem Inc (VSTM) include a net sale of 668 shares made by Daniel Calkins , a net sale of 20,888 shares made by Robert E. Gagnon , and a net sale of 5,805 shares made by Dan Paterson .

In summary, during the past 3 months, insiders sold 1,883 shares of Verastem Inc (VSTM) in total and bought 0 shares, with a net sale of 1,883 shares. During the past 18 months, 32,310 shares of Verastem Inc (VSTM) were sold and 0 shares were bought by its insiders, resulting in a net sale of 32,310 shares.

Verastem Inc (VSTM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Verastem Inc Insider Transactions

No Available Data

What does Rain Oncology Inc do?

Who are the key executives at Rain Oncology Inc?

Bvf Partners L P/il is the director & other: See Remarks of Rain Oncology Inc. Other key executives at Rain Oncology Inc include 10 percent owner Kevin C Tang , Principal Fin. & Acc. Officer Josephine Bruce , and 10 percent owner Tang Capital Management Llc .

Rain Oncology Inc (RAIN) Insider Trades Summary

Over the past 18 months, Bvf Partners L P/il made no insider transaction in Rain Oncology Inc (RAIN). Other recent insider transactions involving Rain Oncology Inc (RAIN) include a net purchase of 1,198,445 shares made by Kevin C Tang , and a net sale of 995,000 shares made by Boxer Capital, Llc .

In summary, during the past 3 months, insiders sold 0 shares of Rain Oncology Inc (RAIN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 1,168,973 shares of Rain Oncology Inc (RAIN) were sold and 1,372,418 shares were bought by its insiders, resulting in a net purchase of 203,445 shares.

Rain Oncology Inc (RAIN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Rain Oncology Inc Insider Transactions

No Available Data

What does Olema Pharmaceuticals inc do?

Who are the key executives at Olema Pharmaceuticals inc?

Bvf Partners L P/il is the director & 10 percent owner & other: See Remarks of Olema Pharmaceuticals inc. Other key executives at Olema Pharmaceuticals inc include 10 percent owner Paradigm Biocapital Advisors Lp , director & Chief Technology Officer Cyrus Harmon , and director & President and CEO Sean Bohen .

Olema Pharmaceuticals inc (OLMA) Insider Trades Summary

Over the past 18 months, Bvf Partners L P/il made no insider transaction in Olema Pharmaceuticals inc (OLMA). Other recent insider transactions involving Olema Pharmaceuticals inc (OLMA) include a net sale of 338,181 shares made by Cyrus Harmon , a net sale of 44,370 shares made by David C. Myles , and a net sale of 2,300,000 shares made by Paradigm Biocapital Advisors Lp .

In summary, during the past 3 months, insiders sold 0 shares of Olema Pharmaceuticals inc (OLMA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 4,048,074 shares of Olema Pharmaceuticals inc (OLMA) were sold and 2,245,932 shares were bought by its insiders, resulting in a net sale of 1,802,142 shares.

Olema Pharmaceuticals inc (OLMA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Olema Pharmaceuticals inc Insider Transactions

No Available Data

What does Cullinan Therapeutics Inc do?

Who are the key executives at Cullinan Therapeutics Inc?

Bvf Partners L P/il is the 10 percent owner of Cullinan Therapeutics Inc. Other key executives at Cullinan Therapeutics Inc include See Remarks Jennifer Michaelson , Acting Chief Business Officer Savill Corrine , and director & President and CEO Nadim Ahmed .

Cullinan Therapeutics Inc (CGEM) Insider Trades Summary

Over the past 18 months, Bvf Partners L P/il made no insider transaction in Cullinan Therapeutics Inc (CGEM). Other recent insider transactions involving Cullinan Therapeutics Inc (CGEM) include a net sale of 94,903 shares made by Jennifer Michaelson , a net sale of 5,708 shares made by Jeffrey Trigilio , and a net sale of 3,027 shares made by Jeffrey Alan Jones .

In summary, during the past 3 months, insiders sold 8,000 shares of Cullinan Therapeutics Inc (CGEM) in total and bought 0 shares, with a net sale of 8,000 shares. During the past 18 months, 231,648 shares of Cullinan Therapeutics Inc (CGEM) were sold and 0 shares were bought by its insiders, resulting in a net sale of 231,648 shares.

Cullinan Therapeutics Inc (CGEM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Cullinan Therapeutics Inc Insider Transactions

No Available Data

What does Repare Therapeutics Inc do?

Who are the key executives at Repare Therapeutics Inc?

Bvf Partners L P/il is the 10 percent owner of Repare Therapeutics Inc. Other key executives at Repare Therapeutics Inc include EVP & Chief Medical Officer Maria Koehler , EVP & Chief Science Officer Michael Zinda , and EVP & Chief Financial Officer Steve Forte .

Repare Therapeutics Inc (RPTX) Insider Trades Summary

Over the past 18 months, Bvf Partners L P/il made no insider transaction in Repare Therapeutics Inc (RPTX). Other recent insider transactions involving Repare Therapeutics Inc (RPTX) include a net sale of 12,683 shares made by Michael Zinda , a net purchase of 2,011,010 shares made by Biotechnology Value Fund L P , and a net sale of 13,091 shares made by Lloyd Mitchell Segal .

In summary, during the past 3 months, insiders sold 0 shares of Repare Therapeutics Inc (RPTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 32,163 shares of Repare Therapeutics Inc (RPTX) were sold and 2,011,010 shares were bought by its insiders, resulting in a net purchase of 1,978,847 shares.

Repare Therapeutics Inc (RPTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Repare Therapeutics Inc Insider Transactions

No Available Data

What does MoonLake Immunotherapeutics do?

Who are the key executives at MoonLake Immunotherapeutics?

Bvf Partners L P/il is the director & 10 percent owner of MoonLake Immunotherapeutics. Other key executives at MoonLake Immunotherapeutics include director & 10 percent owner Biotechnology Value Fund L P , director & Chief Executive Officer Santos Da Silva Jorge , and Chief Scientific Officer Kristian Reich .

MoonLake Immunotherapeutics (MLTX) Insider Trades Summary

Over the past 18 months, Bvf Partners L P/il made no insider transaction in MoonLake Immunotherapeutics (MLTX). Other recent insider transactions involving MoonLake Immunotherapeutics (MLTX) include a net purchase of 802,051 shares made by Bihua Chen , a net sale of 200,000 shares made by Kristian Reich , and a net sale of 184,740 shares made by Santos Da Silva Jorge .

In summary, during the past 3 months, insiders sold 2,171,000 shares of MoonLake Immunotherapeutics (MLTX) in total and bought 0 shares, with a net sale of 2,171,000 shares. During the past 18 months, 2,655,740 shares of MoonLake Immunotherapeutics (MLTX) were sold and 802,051 shares were bought by its insiders, resulting in a net sale of 1,853,689 shares.

MoonLake Immunotherapeutics (MLTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

MoonLake Immunotherapeutics Insider Transactions

No Available Data

What does 4D Molecular Therapeutics Inc do?

Who are the key executives at 4D Molecular Therapeutics Inc?

Bvf Partners L P/il is the 10 percent owner of 4D Molecular Therapeutics Inc. Other key executives at 4D Molecular Therapeutics Inc include Chief Legal and HR Officer Scott Bizily , director & Chief Executive Officer David Kirn , and Chief Medical Officer Robert Young Kim .

4D Molecular Therapeutics Inc (FDMT) Insider Trades Summary

Over the past 18 months, Bvf Partners L P/il made no insider transaction in 4D Molecular Therapeutics Inc (FDMT). Other recent insider transactions involving 4D Molecular Therapeutics Inc (FDMT) include a net sale of 39,883 shares made by Scott Bizily , a net sale of 225,853 shares made by David Kirn , and a net purchase of 310,000 shares made by Viking Global Investors Lp .

In summary, during the past 3 months, insiders sold 1,000 shares of 4D Molecular Therapeutics Inc (FDMT) in total and bought 0 shares, with a net sale of 1,000 shares. During the past 18 months, 830,288 shares of 4D Molecular Therapeutics Inc (FDMT) were sold and 850,000 shares were bought by its insiders, resulting in a net purchase of 19,712 shares.

4D Molecular Therapeutics Inc (FDMT)'s detailed insider trading history can be found in Insider Trading Tracker table.

4D Molecular Therapeutics Inc Insider Transactions

No Available Data

What does ESSA Pharma Inc do?

Who are the key executives at ESSA Pharma Inc?

Bvf Partners L P/il is the 10 percent owner of ESSA Pharma Inc. Other key executives at ESSA Pharma Inc include Chief Operating Officer Peter Virsik , director & Chief Executive Officer David Ross Parkinson , and Chief Financial Officer David S. Wood .

ESSA Pharma Inc (EPIX) Insider Trades Summary

Over the past 18 months, Bvf Partners L P/il made no insider transaction in ESSA Pharma Inc (EPIX). Other recent insider transactions involving ESSA Pharma Inc (EPIX) include a net sale of 81,945 shares made by Peter Virsik , a net purchase of 99,730 shares made by Franklin M Berger , and a net purchase of 9,223 shares made by David Ross Parkinson .

In summary, during the past 3 months, insiders sold 3,470 shares of ESSA Pharma Inc (EPIX) in total and bought 0 shares, with a net sale of 3,470 shares. During the past 18 months, 81,945 shares of ESSA Pharma Inc (EPIX) were sold and 108,953 shares were bought by its insiders, resulting in a net purchase of 27,008 shares.

ESSA Pharma Inc (EPIX)'s detailed insider trading history can be found in Insider Trading Tracker table.

ESSA Pharma Inc Insider Transactions

No Available Data

What does Third Harmonic Bio Inc do?

Who are the key executives at Third Harmonic Bio Inc?

Bvf Partners L P/il is the 10 percent owner of Third Harmonic Bio Inc. Other key executives at Third Harmonic Bio Inc include other: See Explanation of Responses Biotechnology Value Fund L P , Chief Medical Officer Edward R. Conner , and Chief Administrative Officer Julie Person .

Third Harmonic Bio Inc (THRD) Insider Trades Summary

Over the past 18 months, Bvf Partners L P/il made no insider transaction in Third Harmonic Bio Inc (THRD). Other recent insider transactions involving Third Harmonic Bio Inc (THRD) include a net sale of 33,970 shares made by Julie Person , a net sale of 25,114 shares made by , and a net sale of 12,253 shares made by Edward R. Conner .

In summary, during the past 3 months, insiders sold 1,017,463 shares of Third Harmonic Bio Inc (THRD) in total and bought 0 shares, with a net sale of 1,017,463 shares. During the past 18 months, 1,105,117 shares of Third Harmonic Bio Inc (THRD) were sold and 0 shares were bought by its insiders, resulting in a net sale of 1,105,117 shares.

Third Harmonic Bio Inc (THRD)'s detailed insider trading history can be found in Insider Trading Tracker table.

Third Harmonic Bio Inc Insider Transactions

No Available Data

What does Structure Therapeutics Inc do?

Who are the key executives at Structure Therapeutics Inc?

Bvf Partners L P/il is the 10 percent owner of Structure Therapeutics Inc. Other key executives at Structure Therapeutics Inc include other: See Explanation of Responses Biotechnology Value Fund L P , 10 percent owner Bvf Gp Holdings Llc , and other: See Explanation of Responses Bvf Ii Gp Llc .

Structure Therapeutics Inc (GPCR) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Structure Therapeutics Inc (GPCR) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Structure Therapeutics Inc (GPCR) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Structure Therapeutics Inc (GPCR)'s detailed insider trading history can be found in Insider Trading Tracker table.

Structure Therapeutics Inc Insider Transactions

No Available Data

What does POINT Biopharma Global Inc do?

Who are the key executives at POINT Biopharma Global Inc?

Bvf Partners L P/il is the 10 percent owner of POINT Biopharma Global Inc. Other key executives at POINT Biopharma Global Inc include other: See Explanation of Responses Biotechnology Value Fund L P , 10 percent owner Bvf Inc/il , and 10 percent owner Bvf Gp Holdings Llc .

POINT Biopharma Global Inc (PNT) Insider Trades Summary

Over the past 18 months, Bvf Partners L P/il made no insider transaction in POINT Biopharma Global Inc (PNT). Other recent insider transactions involving POINT Biopharma Global Inc (PNT) include a net sale of 17,161,278 shares made by Biotechnology Value Fund L P ,

In summary, during the past 3 months, insiders sold 0 shares of POINT Biopharma Global Inc (PNT) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 17,161,278 shares of POINT Biopharma Global Inc (PNT) were sold and 0 shares were bought by its insiders, resulting in a net sale of 17,161,278 shares.

POINT Biopharma Global Inc (PNT)'s detailed insider trading history can be found in Insider Trading Tracker table.

POINT Biopharma Global Inc Insider Transactions

No Available Data

Bvf Partners L P/il Mailing Address

Above is the net worth, insider trading, and ownership report for Bvf Partners L P/il. You might contact Bvf Partners L P/il via mailing address: 44 Montgomery St., 40th Floor, San Francisco Ca 94104.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.